Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Pixium Vision

Pixium Vision

To provide in class bionic vision restoration systems enabling the blind to regain greater autonomy and improved quality of daily living.

Pixium Vision, created in December 2011, is a bioelectronics and brain machine interface technology company specialized in neuromodulation application whose mission is to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy.

Prima System features a miniaturized and totally wireless sub-retinal PRIMA implant, a pocket computer equipped with breakthrough algorithms, and a pair of glasses which captures the visual scene.

For the novel breakthrough Prima system, the exclusive transfer of the patented technology was granted by Stanford’s University to Pixium Vision to develop and industrialize the PRIMA bionic vision system.

Pixium Vision is currently conducting in France and in the United States, two feasibility clinical trials with PRIMA, for patients with severe vision loss due to retinal degeneration caused by the dry atrophic form of Age-related Macular Degeneration (AMD), for which there is no treatment available to date.


January 6, 2022
Pixium Vision to attend BIOMED EVENT® by Invest Securities on January 26, 2022
December 14, 2021
Pixium Vision to attend 11th Annual LifeSci Partners Corporate Access Event
November 25, 2021
Pixium Vision to present at BTIG's Ophthalmology Day
November 25, 2013
Pixium Vision raises a $19,299,000 series A round from Abingworth, Omnes Capital and Sofinnova Partners.

Funding Rounds


Further Resources



Conor Hale
May 21, 2021
The classic eye chart wall poster is getting an upgrade, with newcomer Heru looking to bring vision tests into virtual reality.
Carla Mozée
March 5, 2021
Business Insider
Second Sight shares jumped to $9.89 before paring gains. Volume of 613 million shares was much heavier than the average daily volume of 3.11 million.


Golden logo
By using this site, you agree to our Terms & Conditions.